[Acute myocardial infarction].
Patients with acute myocardial infarction as well as high risk patients for coronary artery disease has been shown to receive benefits from angiotensin-converting enzymes. Since angiotensin receptor blocker(ARB) provides more complete blockade of the RAA system, treatment with ARB may bring more fruitful results. In this article, secondary prevention trials(OPTIMAAL and VALIANT) for patients with acute myocardial infarction and primary prevention trials(LIFE, SCOPE, and VALUE) were reviewed.
Sato
Hiroshi
H
Osaka University Graduate School of Medicine.
D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D002216:Captopril / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D023903:Coronary Restenosis / Q000517:prevention & control; D005260:Female; D006801:Humans; D019808:Losartan / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000517:prevention & control*; D013777:Tetrazoles / Q000627:therapeutic use; D014633:Valine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000068756:Valsartan
D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D013777:Tetrazoles; D000068756:Valsartan; D002216:Captopril; D014633:Valine; D019808:Losartan